TrialSignal transduction and targeted therapy2025

Reshaping the tumor microenvironment of cold soft-tissue sarcomas with anti-angiogenics: a phase 2 trial of regorafenib combined with avelumab.

Maud Toulmonde et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.